三金SANJIN品牌怎么样 申请店铺

我要投票 三金SANJIN在口气清新剂行业中的票数:243 更新时间:2025-02-23
三金SANJIN是哪个国家的品牌?「三金SANJIN」是 桂林三金药业股份有限公司 旗下著名品牌。该品牌发源于广西,由创始人邹节明在1994期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三金SANJIN品牌出海!通过在本页面挂载三金SANJIN品牌的产品链接和联系邮箱,可以提高三金SANJIN产品曝光!跨境电商爆单神器,目前只要100元/年哦~

三金SANJIN怎么样

桂林三金药业股份有限公司是三金集团的核心企业,主营中成药、天然药物的研发和生产,是国内较早生产现代中药制剂的厂家之一,也是广西医药龙头企业。1985年以来,桂林三金坚持改革创新,依靠科技进步和科学管理,从一个名不见经传的中药作坊小厂蜕变成为全国知名的现代中药企业。

三金作为区内外知名的高新技术企业,建有国家认定的企业技术中心、博士后科研工作站及广西中药产业化工程院等创新平台。多年来,一直致力推进和实施中药产业现代化规划,积极培养、提高企业的自主创新能力。目前公司的特色中药新药均由企业技术中心主导研制。目前,三金拥有200多个注册品种和13个药品剂型,拥有桂林西瓜霜、西瓜霜润喉片、三金片、脑脉泰胶囊等自主开发的特色品种42种。经过多年努力,三金在咽喉、口腔用药和泌尿系统用药方面已形成较强的专业和市场优势,代表产品三金西瓜霜系列、三金片。“三金”牌产品已行销海内外,并享有良好声誉。

2009年7月,桂林三金以高成长、高效益的崭新面貌,成功进入资本市场,迎来企业高速发展的新阶段。近年来,为积极响应桂林市委、市政府“向西发展,再造一个新桂林”的号召,也为解决企业生产基地及仓储设施分散与企业快速发展之间的矛盾,三金启动了“三金现代中药产业化技术改造工程”的建设。目前,该项目一期已经正式投产并实现了主要生产线的整体搬迁。

面对未来,三金将秉承“创新推动医药进步”的企业使命和“敢为先”企业精神,实施以中药制药为主体,致力发展生物制药和大健康产业的”一体两翼”发展战略,视质量、信誉为企业第一生命,突破创新,不断增强三金的竞争实力,锐意进取,以发展报国、回报投资者,以打造中国知名医药制造集团为目标,推动中药产业现代化、国际化!


Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin group, which is mainly engaged in the research and development and production of Chinese patent medicine and natural medicine. It is one of the earliest manufacturers of modern Chinese medicine preparations in China, and also the leading enterprise of Guangxi medicine. Since 1985, Guilin Sanjin has persisted in reform and innovation, relying on scientific and technological progress and scientific management, and has transformed from an unknown small traditional Chinese medicine workshop into a well-known modern Chinese medicine enterprise in China. As a well-known high-tech enterprise inside and outside the zone, Sanjin has established a national recognized enterprise technology center, postdoctoral research workstation, Guangxi Institute of traditional Chinese medicine industrialization and other innovation platforms. Over the years, we have been committed to promoting and implementing the modernization plan of traditional Chinese medicine industry, and actively cultivating and improving the independent innovation ability of enterprises. At present, the company's characteristic new Chinese medicine is mainly developed by the enterprise technology center. At present, Sanjin has more than 200 registered varieties and 13 pharmaceutical dosage forms, and 42 self-developed characteristic varieties such as Guilin Watermelon cream, watermelon cream throat moistening tablet, Sanjin tablet, Naomaitai Capsule, etc. After years of efforts, Sanjin has formed strong professional and market advantages in throat, oral medicine and urinary system medicine, representing Sanjin watermelon cream series and Sanjin tablets. "Three gold" brand products have been sold at home and abroad, and enjoy a good reputation. In July 2009, Guilin Sanjin successfully entered the capital market and ushered in a new stage of rapid development of enterprises with a new look of high growth and high efficiency. In recent years, in order to actively respond to the call of Guilin municipal Party committee and municipal government to "develop to the West and rebuild a new Guilin", and to solve the contradiction between the scattered production base and storage facilities of enterprises and the rapid development of enterprises, Sanjin has launched the construction of "Sanjin modern Chinese medicine industrialization technology transformation project". At present, the first phase of the project has been officially put into operation and the overall relocation of the main production lines has been realized. In the future, Sanjin will adhere to the enterprise mission of "innovation promotes pharmaceutical progress" and the enterprise spirit of "dare to be the first", implement the development strategy of "one body and two wings" with traditional Chinese medicine as the main body, devote to the development of biopharmaceutical and big health industry, regard quality and reputation as the life of the enterprise, break through innovation, continuously enhance the competitiveness of Sanjin, forge ahead, serve the country and return with development Newspaper investors, with the goal of building a well-known Chinese pharmaceutical manufacturing group, to promote the modernization and internationalization of traditional Chinese medicine industry!

本文链接: https://brand.waitui.com/7e6028fbc.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

2小时前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

2小时前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

2小时前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

2小时前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

本页详细列出关于屈臣氏Watsons的品牌信息,含品牌所属公司介绍,屈臣氏Watsons所处行业的品牌地位及优势。
咨询